Pliant Therapeutics Inc (PLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.23 Million) by net assets ($165.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Pliant Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Pliant Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pliant Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pliant Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
-0.917x |
|
Hannan Metals Ltd
V:HAN
|
-0.019x |
|
Daidong Elec
KO:008110
|
0.017x |
|
Sun Max Tech Ltd
TW:6591
|
0.024x |
|
DocCheck AG
XETRA:AJ91
|
0.043x |
|
Sempio Foods Co
KO:248170
|
0.068x |
|
Sinkang Industries Co Ltd
TW:2032
|
0.011x |
|
Westwater Resources Inc
NYSE MKT:WWR
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Pliant Therapeutics Inc (PLRX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $181.21 Million | $-128.34 Million | -0.708x | -38.49% |
| 2024-12-31 | $304.08 Million | $-155.50 Million | -0.511x | -108.13% |
| 2023-12-31 | $473.58 Million | $-116.36 Million | -0.246x | +18.64% |
| 2022-12-31 | $313.34 Million | $-94.63 Million | -0.302x | +20.31% |
| 2021-12-31 | $199.06 Million | $-75.44 Million | -0.379x | -187.84% |
| 2020-12-31 | $283.06 Million | $-37.27 Million | -0.132x | -102.08% |
| 2019-12-31 | $-435.00K | $-2.75 Million | 6.322x | -80.32% |
| 2018-12-31 | $-882.00K | $-28.33 Million | 32.118x | +738.60% |
| 2017-12-31 | $3.37 Million | $-16.92 Million | -5.029x | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more